Monday 23 November 2026

ASX Announcement

Control Bionics pauses new NDIS-funded communication device applications in Australia

Key points

- Control Bionics will pause new NDIS-funded applications for its augmentative and alternative communication (AAC) products in Australia from 23 November 2026 due to ongoing delays in National Disability Insurance Agency (NDIA) funding decisions.
- The decision does not change the company's FY27 guidance of 50% revenue growth.
- New enquiries for NDIS funded devices will be referred to third-party suppliers with whom Control Bionics already has international distribution arrangements, transitioning the Australian NDIS AAC business to a wholesale model strategy similar to the US and Europe.
- 55 participant applications, valued at $626,290, are awaiting a NDIA decision. The median wait time is 334 days, with the longest at 1,000 days for approval. In addition, all applications that have completed a trial, with a combined value of $307,098, will be lodged with NDIS by 18 December 2026.
- All previously lodged applications will be supported by Control Bionics and existing customers will continue to receive full support.
- The balance of Control Bionics' Australian business continues unaffected.

Control Bionics Limited (ASX: CBL) today announced it will pause new National Disability Insurance Scheme (NDIS)-funded applications for its augmentative and alternative communication (AAC) products in Australia, effective 23 November 2026.

This decision is a result of ongoing delays in National Disability Insurance Agency (NDIA) funding decisions for assistive technology. All applications that have completed a trial, with a combined value of $307,098, must be lodged with the NDIA by 18 December 2026. No new applications will be submitted after this date while the pause remains in effect.

Control Bionics CEO Jeremy Steele said, “Our technology helps people with significant disabilities communicate and improve their quality of life. It is not fair or reasonable to train people and their carers to use it, then leave them waiting several months, or even a year, to find out if their device will be funded.”

“The delays are industry wide and affect other assistive technology suppliers. We will continue to work with the NDIA and the Australian Government to address them. In the meantime, we cannot in good faith ask more people to begin the process knowing how long they may have to wait.”

“We remain committed to supporting our existing customers and every participant whose application is already in progress. The Company will consider lifting the pause once the NDIA consistently meets its legislated timeframes.”

As of 18 November 2026, Control Bionics had 55 applications awaiting a NDIA decision, valued at $626,290. The median wait time was 334 days, with the longest at 1,000 days.

Since December 2024, 62% of applications by NDIS participants requesting the technology have been waiting between six to 18 months without a response from NDIA. One application took 733 days from submission to approval.

Under the Participant Service Guarantee, the NDIA must decide a plan variation request within 21 days or, where it needs more time, within 28 days and 50 days for complex needs.

For the June 2026 quarter, the NDIA said it met its 28-day standard 44% of the time.

Control Bionics funds training for participants and carers, provides ongoing technical and clinical support, and assists with applications. The Company is paid when the NDIA approves a device and it is delivered to the participant.

The pause applies only to new NDIS-funded AAC applications in Australia and covers:

- New trials for NDIS participants,
- New NDIS quotes and funding applications, except those already in preparation, which will be lodged by 18 December 2026, and

- Clinical and sales support for new NDIS participants.

The pause does not affect:

- Applications already lodged with the NDIA will be supplied as quoted if approved, with quoted prices held until 30 June 2027.
- Trials already under way, which will be completed as scheduled.
- Warranty, repairs, service, electrodes and technical support for all existing NeuroNode users, including NDIS-funded repairs and consumables.
- Referral of new NDIS enquiries to third-party suppliers Tobii Dynavox and Liberator (PRC-Saltillo), who can already sell NeuroNode devices in Australia.
- Direct sales in Australia funded outside the NDIS, including aged care, state schemes, Department of Veterans' Affairs (DVA), health services, and private purchasers.
- The Company's global AAC business through its distribution partners in the US, Germany, and other markets.
- NeuroStrip and the Company's other business pillars.

Control Bionics remains a registered NDIS provider and the Australian Register of Therapeutic Goods (ARTG) sponsor for NeuroNode in Australia.

The Company is notifying the NDIA and the NDIS Quality and Safeguards Commission today and has written to the NDIA's Chief Executive Officer and the Minister responsible for the NDIS with a schedule of pending applications, requesting a decision on each within 21 days and a single NDIA contact for the batch.

Control Bionics' NeuroNode is a wearable sensor that detects signals from tiny muscle movements, or attempts to move, and turns them into commands that control a tablet or speech-generating device. People with MND, Cerebral Palsy, locked-in syndrome and similar conditions use it to speak through a synthesised voice, write and stay connected. It keeps working as their condition progresses.

This announcement has been authorised for release by the Board of Control Bionics Limited.

Jeremy Steele
CEO and Managing Director
jsteele@controlbionics.com

Brett Crowley
Company Secretary
brettcrowley@controlbionics.com

About Control Bionics

Control Bionics Limited is a neurotechnology company commercialising objective, non-invasive neural-signal technology proven in clinical environments and built to scale across multiple markets. Its neural-signal platform captures the body's physiological signals, including the electrical activity generated by muscles, with medical-grade precision and converts them into measurable, decision-ready outcomes. A single underlying technology platform serves four applications: Performance, Rehabilitation, Research & Data, and Assistive Communication. The technology has historically been deployed in assistive communication and is now being extended into sports performance, rehabilitation, medical research, platform partnerships and broader human-computer interface applications. Control Bionics' technology does not require surgery or implantation, and holds regulatory clearances in the US, Australia and Europe. The Company is also a registered NDIS provider in Australia.